Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273

1.

Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006.

McNicholas A, Galloway Y, Stehr-Green P, Reid S, Radke S, Sexton K, Kieft C, Macdonald C, Neutze J, Drake R, Isaac D, O'Donnell M, Tatley M, Oster P, O'Hallahan J.

Hum Vaccin. 2007 Sep-Oct;3(5):196-204. Epub 2007 May 18.

PMID:
17660718
2.

Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.

Wong SH, Lennon DR, Jackson CM, Stewart JM, Reid S, Ypma E, O'Hallahan JM, Oster P, Mulholland K, Martin DR.

Pediatr Infect Dis J. 2009 May;28(5):385-90. doi: 10.1097/INF.0b013e318195205e.

PMID:
19384263
3.

Phase II meningococcal B vesicle vaccine trial in New Zealand infants.

Jackson C, Lennon DR, Sotutu VT, Yan J, Stewart JM, Reid S, Crengle S, Oster P, Ypma E, Aaberge I, Mulholland K, Martin DR.

Arch Dis Child. 2009 Oct;94(10):745-51. doi: 10.1136/adc.2007.132571. Epub 2008 Oct 6.

PMID:
18838420
4.

Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.

Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S.

Clin Infect Dis. 2009 Aug 15;49(4):597-605. doi: 10.1086/603552. Review.

PMID:
19622040
5.

The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.

Sexton K, Lennon D, Oster P, Crengle S, Martin D, Mulholland K, Percival T, Reid S, Stewart J, O'Hallahan J.

N Z Med J. 2004 Aug 20;117(1200):U1015.

PMID:
15475985
6.

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.

Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J.

Int J Epidemiol. 2009 Apr;38(2):413-8. doi: 10.1093/ije/dyn228. Epub 2008 Nov 6.

PMID:
18988650
7.

Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.

Arnold R, Galloway Y, McNicholas A, O'Hallahan J.

Vaccine. 2011 Sep 16;29(40):7100-6. doi: 10.1016/j.vaccine.2011.06.120. Epub 2011 Jul 29.

PMID:
21803101
8.

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.

N√łkleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P.

Vaccine. 2007 Apr 20;25(16):3080-4. Epub 2007 Jan 22.

PMID:
17287053
9.

New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.

Wong S, Lennon D, Jackson C, Stewart J, Reid S, Crengle S, Tilman S, Aaberge I, O'Hallahan J, Oster P, Mulholland K, Martin D.

Pediatr Infect Dis J. 2007 Apr;26(4):345-50.

PMID:
17414400
10.

Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.

Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, Toneatto D, Pollard AJ.

Pediatr Infect Dis J. 2010 Nov;29(11):e71-9. doi: 10.1097/INF.0b013e3181f59f6d.

PMID:
20844462
11.

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.

Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D.

Vaccine. 2007 Apr 20;25(16):3075-9. Epub 2007 Jan 22.

PMID:
17289223
12.

Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.

Hosking J, Rasanathan K, Mow FC, Jackson C, Martin D, O'Hallahan J, Oster P, Ypma E, Reid S, Aaberge I, Crengle S, Stewart J, Lennon D.

Clin Vaccine Immunol. 2007 Nov;14(11):1393-9. Epub 2007 Sep 26.

13.

The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand.

Stehr-Green P, Radke S, Kieft C, Galloway Y, McNicholas A, Reid S.

Vaccine. 2008 Feb 6;26(6):739-42. doi: 10.1016/j.vaccine.2007.12.001. Epub 2007 Dec 26.

PMID:
18187240
14.

The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand.

Tatley MV, Kunac DL, McNicholas A, Zhou L, Ballantyne S, Ashton J, Stehr-Green P, Galloway Y, Reid S.

Vaccine. 2008 May 23;26(22):2746-52. doi: 10.1016/j.vaccine.2008.03.017. Epub 2008 Apr 1.

PMID:
18430496
15.

The strategy to control New Zealand's epidemic of group B meningococcal disease.

O'Hallahan J, Lennon D, Oster P.

Pediatr Infect Dis J. 2004 Dec;23(12 Suppl):S293-8.

PMID:
15597072
16.

Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease.

O'Hallahan J, McNicholas A, Galloway Y, O'Leary E, Roseveare C.

N Z Med J. 2009 Mar 13;122(1291):48-59.

PMID:
19322255
17.

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.

Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E.

Vaccine. 2009 Jun 24;27 Suppl 2:B3-12. doi: 10.1016/j.vaccine.2009.04.071. Epub 2009 May 28. Review.

PMID:
19481313
18.

Challenges and progress in the development of a serogroup B meningococcal vaccine.

Lewis S, Sadarangani M, Hoe JC, Pollard AJ.

Expert Rev Vaccines. 2009 Jun;8(6):729-45. doi: 10.1586/erv.09.30. Review.

PMID:
19485754
19.

Meningococcal serogroup B infections: a search for a broadly protective vaccine.

Vermont CL, van den Dobbelsteen GP.

Expert Rev Vaccines. 2003 Oct;2(5):673-81. Review.

PMID:
14711328
20.

A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.

Kelly C, Arnold R, Galloway Y, O'Hallahan J.

Am J Epidemiol. 2007 Oct 1;166(7):817-23. Epub 2007 Jul 5.

PMID:
17615088

Supplemental Content

Support Center